PRV 6527

Drug Profile

PRV 6527

Alternative Names: JNJ-244; JNJ-40346527; JNJ-527; PRV-6527

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development; Provention Bio
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease
  • Discontinued Hodgkin's disease; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 21 Sep 2017 JNJ 4036527 licensed to Provention Bio
  • 21 Sep 2017 Provention Bio plans a phase IIa trial for Crohn's disease in first half of 2018
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top